Definitive Healthcare Corp. (DH) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. Definitive Healthcare Corp. is a leading provider of healthcare data and analytics, serving approximately 2,200 customers across Life Sciences, Provider, and Diversified markets. The company operates as a single reporting segment, deriving the majority of its revenue from subscription services.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $55.2 million | $60.8 million | $111.1 million | $119.9 million |
| Gross Profit | $40.5 million (73% margin) | $46.6 million (77% margin) | $82.2 million (74% margin) | $90.4 million (75% margin) |
| Net Loss (GAAP) | $(7.5) million | $(9.3) million | $(199.8) million | $(164.4) million |
| Net Loss Attributable to DH | $(5.4) million | $(7.6) million | $(144.0) million | $(114.8) million |
| Adjusted EBITDA | $14.6 million (26% margin) | $18.7 million (31% margin) | $29.9 million (27% margin) | $33.4 million (28% margin) |
| Cash and Equivalents | $170.9 million (as of June 30, 2026) | |||
| Short-Term Investments | $12.7 million (as of June 30, 2026) | |||
| Debt (Term Loan Principal) | $161.9 million (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 9% year-over-year in Q2 and 7% year-over-year for the six months ended June 30, 2026. This was driven by a decrease in revenue from existing customers ($7.8 million in Q2; $12.0 million YTD), partially offset by new customer revenue. Management cites sales execution challenges and macroeconomic headwinds.
- Goodwill Impairment: A significant non-cash goodwill impairment charge of $197.2 million was recorded in Q1 2026 (included in YTD results), triggered by a decline in market capitalization. This charge reduced the goodwill balance to zero. A similar charge of $176.5 million occurred in Q1 2025.
- Operating Expenses: Excluding goodwill impairment, operating expenses decreased due to cost-cutting measures, including a restructuring plan reducing the workforce by approximately 40 people. Stock-based compensation also declined due to lower stock prices and headcount reductions.
- Liquidity: Cash and cash equivalents increased to $170.9 million from $163.6 million at year-end 2025. The company generated $23.0 million in operating cash flow for the six months ended June 30, 2026.
Guidance, Outlook, and Risks
- Outlook: Management expects revenue to decline in 2026 compared to 2025 due to sales execution challenges and macroeconomic conditions. They anticipate negative revenue growth for the full year.
- Nasdaq Compliance Risk: On June 18, 2026, the company received notice from Nasdaq regarding non-compliance with the minimum bid price requirement (stock closed below $1.00 for 30 consecutive days). The company has 180 days (until December 15, 2026) to regain compliance or face potential delisting.
- Restructuring: The "2026 Restructuring Plan" aims to reduce costs and improve margins. Approximately $1.1 million in charges were incurred in Q1, with remaining payments expected over the next three months.
- Product Innovation: The company is piloting "Turbo," an AI-powered healthcare intelligence platform, with select strategic customers in Q3 2026.
- Tax Receivable Agreement (TRA): The company recorded a $6.6 million gain on the remeasurement of the TRA liability in the first six months of 2026. The TRA liability stands at $12.0 million.
Investor Verification Checklist
- Delisting Risk: Verify the company's plan to regain Nasdaq compliance (e.g., reverse stock split) before the December 15, 2026 deadline.
- Revenue Trends: Monitor customer churn rates and the success of the new "Turbo" AI platform in stabilizing or growing revenue.
- Goodwill Status: Confirm that the $197.2 million impairment has fully written off the goodwill balance, eliminating future impairment risk for this asset class.
- Debt Covenants: Review the 2021 Credit Agreement covenants to ensure the company remains in compliance despite the revenue decline and net losses.
- TRA Liability: Assess the impact of future LLC unit exchanges on the Tax Receivable Agreement liability and cash outflows.